Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 12Recruiting 6Active not recruiting 5Terminated 4Unknown 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Small Cell Lung Carcinoma 7Carcinoma, Hepatocellular 7Urinary Bladder Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Melanoma 4Lung Neoplasms 4Head and Neck Neoplasms 4Biliary Tract Neoplasms 4Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma, Renal Cell 3Stomach Neoplasms 2Recurrence 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Lymphoma 2Liver Neoplasms 2Esophageal Neoplasms 2Endometrial Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Merkel Cell 2Bile Duct Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Unresectable Stage III NSCLC 1Triple Negative Breast Neoplasms 1Resectable Biliary Tract Cancer 1Radiation Pneumonitis 1

Interventions

Exercise 19Drug Therapy 18pembrolizumab 13Capecitabine 11Blood Specimen Collection 11Surveys and Questionnaires 10Radiotherapy 10Paclitaxel 9Dexamethasone 9Nivolumab 8Standard of Care 7Oxaliplatin 7Fluorouracil 7Erlotinib Hydrochloride 7apatinib 6Interviews as Topic 6Gemcitabine 6Control Groups 6Cisplatin 6Therapeutics 5Neoadjuvant Therapy 5Mindfulness-Based Cognitive Therapy 5Metformin 5Injections 5Everolimus 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5sintilimab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Neoplasms × durvalumab × Clear all
NCT03759496 2022-03-23

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Hellenic GenitoUrinary Cancer Group

Phase 2 Unknown
39 enrolled
Genitourinary

Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡